Immunovia interim report January-September 2018
Immunovia’s IMMray™ platform for blood-based biomarker signatures offers exciting new opportunities to develop accurate diagnostic tests that can detect diseases at an early stage. During the period we presented new results and identified no fewer than two new areas for strategic focus in our ongoing development activities – non-small cell lung cancer and Rheumatoid Arthritis (RA). In August we presented the results from our first collaboration trial with a global, top-ten pharmaceutical business. The results showed that Immunovia’s blood-based IMMray™ biomarker array produced very high